Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset

JACC: Clinical Electrophysiology

Volumn 2, Issue 4, 2016, Pages 487-494

  Garg, Aatish ^a   Khunger, Monica ^a   Seicean, Sinziana ^a   Chung, Mina K ^a   Tchou, Patrick J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

atrial fibrillation; cardioversion; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; CLOPIDOGREL; DABIGATRAN; HEPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VASCULAR DISEASE;

EID: 84990859035     PISSN: 2405500X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacep.2016.01.018     Document Type: Article

References (31)

1. 1 Heeringa, J., Kuip, D.A., Hofman, A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J 27 (2006), 949–953.
2. 2 Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
3. 3 Lin, H.J., Wolf, P.A., Kelly-Hayes, M., et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 27 (1996), 1760–1764.
4. 4 Stoddard, M.F., Dawkins, P.R., Prince, C.R., Ammash, N.M., Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 25 (1995), 452–459.
5. 5 Manning, W.J., Silverman, D.I., Waksmonski, C.A., Oettgen, P., Douglas, P.S., Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 155 (1995), 2193–2198.
6. 6 Bjerkelund, O., Orning, O.M., The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 23 (1969), 208–216.
7. 7 Lown, B., Perlroth, M.G., Kaidbey, S., Abe, T., Harken, D.E., “Cardioversion” of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med 269 (1963), 325–331.
8. 8 Weinberg, D.M., Mancini, J., Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 53 (1989), 745–746.
9. 9 Hansen, M.L., Jepsen, R.M., Olesen, J.B., et al. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace 17 (2015), 18–23.
10. 10 Berger, M., Schweitzer, P., Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 82 (1998), 1545–1547 A8.
11. 11 Klein, A.L., Grimm, R.A., Murray, R.D., et al., for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (2001), 1411–1420.
12. 12 Camm, A.J., Kirchhof, P., Lip, G.Y., et al. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429.
13. 13 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol 64 (2014), e1–e76.
14. 14 You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e531S–e575S.
15. 15 Gage, B.F., Waterman, A.D., Shannon, W., et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 285 (2001), 2864–2870.
16. 16 Lip, G.Y., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
17. 17 Von Besser, K., Mills, A.M., Is discharge to home after emergency department cardioversion safe for the treatment of recent-onset atrial fibrillation?. Ann Emerg Med 58 (2011), 517–520.
18. 18 Vinson, D.R., Hoehn, T., Graber, D.J., Williams, T.M., Managing emergency department patients with recent-onset atrial fibrillation. J Emerg Med 42 (2012), 139–148.
19. 19 Burton, J.H., Vinson, D.R., Drummond, K., et al. Electrical cardioversion of emergence department patients with atrial fibrillation. Ann Emerg Med 44 (2004), 20–30.
20. 20 Jacoby, J.L., Cesta, M., Heller, M.B., Salen, P., Reed, J., Synchronized emergency department cardioversion of atrial fibrillation saves time, money and resources. J Emerg Med 28 (2005), 27–30.
21. 21 Stiell, I.G., Clement, C.M., Perry, J.J., et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM 12 (2010), 181–191.
22. 22 Xavier Scheuermeyer, F., Grafstein, E., Stenstrom, R., et al. Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med 17 (2010), 408–415.
23. 23 Weigner, M.J., Caulfield, T.A., Danias, P.G., Silverman, D.I., Manning, W.J., Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 126 (1997), 615–620.
24. 24 Airaksinen, K.E., Grönberg, T., Nuotio, I., et al. Thromboembolic complications after cardioversion of acute atrial fibrillation of acute atrial fibrillation: the FinCV (Finnish Cardioversion) Study. J Am Coll Cardiol 62 (2013), 1187–1192.
25. 25 Ahmad, Y., Lip, G.Y., Apostolakis, S., New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther 10 (2012), 1471–1480.
26. 26 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
27. 27 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
28. 28 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–989.
29. 29 Grond, M., Jauss, M., Hamann, G., et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 44 (2013), 3357–3364.
30. 30 Salvatori, V., Becattini, C., Laureti, S., et al. Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. Intern Emerg Med 10 (2015), 595–601.
31. 31 Glotzer, T.V., Daoud, E.G., Wyse, G., et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS Study. Circ Arrhythm Electrophysiol 2 (2009), 474–480.